Completed PHASE4 INTERVENTIONAL 2-arm NCT03389490

Toujeo Versus NPH Self-titration Study

A Pilot Study to Describe the Glycaemic Variability of Insulin Glargine 300U/ml Versus NPH (Neutral Protamine Hagedorn) in the Insulin-naïve Type 2 Diabetes Patients Following a Patient-adjusted Insulin Algorithm in Hong Kong

Sponsor: Elaine Chow

Conditions Diabetes Mellitus, Type 2

Interventions Insulin Glargine 300 UNT/ML Neutral protamine hagedorn insulin

Updated 6 times since 2018 Last updated: Aug 2, 2021 Started: Jan 1, 2018 Primary completion: Dec 17, 2019 Completion: May 1, 2020

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates Diabetes Mellitus, Type 2 and is currently completed. Elaine Chow leads this study, which shows 6 recorded versions since 2018 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Sep 2021 — Jul 2024 [monthly]

Completed PHASE4

Status: Recruiting → Completed
Jan 2021 — Sep 2021 [monthly]

Recruiting PHASE4
Aug 2019 — Jan 2021 [monthly]

Recruiting PHASE4

Status: Not Yet Recruiting → Recruiting

▶ Show 1 earlier version

Jan 2018 — Aug 2019 [monthly]

Not Yet Recruiting PHASE4

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Elaine Chow
Sanofi

Data source: Chinese University of Hong Kong

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Hong Kong, Hong Kong